Literature DB >> 18383415

Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis.

Chenglong Han1, Josef Smolen, Arthur Kavanaugh, E William St Clair, Daniel Baker, Mohan Bala.   

Abstract

OBJECTIVE: To compare employability between patients with early and long-standing rheumatoid arthritis (RA) and examine the relationships between improvement in employability and disease stage after adjustment for demographic characteristics, disease activity, physical functioning, and response to therapy.
METHODS: We evaluated the employability data from 2 double-blind, randomized, placebo-controlled studies of infliximab plus methotrexate (MTX) in patients with RA. Patients were incomplete responders to MTX in 1 study and had never taken MTX in the other study. Patients age <65 years were categorized as having early RA (< or =3 years disease duration) or long-standing RA (>3 years disease duration). Physical functioning was assessed using the Health Assessment Questionnaire (HAQ) and clinical response was determined based on the American College of Rheumatology 20% improvement criteria (ACR20).
RESULTS: Patients with early RA were more likely to be employable at baseline than those with long-standing RA, even after adjusting for baseline HAQ scores. Among patients who were not employable at baseline but achieved an ACR20 response after 1 year of treatment, after adjusting for baseline HAQ score, the patients with early RA who had never taken MTX were 3 times more likely to become employable compared with those with long-standing RA who had an incomplete response to MTX at baseline.
CONCLUSION: In 2 clinical trials, patients with early RA were more likely to show improved employment outcomes after treatment than those with long-standing RA, suggesting intervention as early as possible in the disease course maximizes an individual patient's employment potential.

Entities:  

Mesh:

Year:  2008        PMID: 18383415     DOI: 10.1002/art.23541

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

2.  Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.

Authors:  Maria N Tamborenea; Cecilia Pisoni; Sergio Toloza; Eduardo Mysler; Guillermo Tate; Dora Pereira; M García Carrasco; J Quintero; A Cappuccio; A Granel; M Lazaro; Pablo Arturi; Gustavo Citera; J Velazco Zamora; Veronica Saurit; A Alvarellos; S B Pons Estel; C Danielsen; C Graf; Sergio Paira; F Ceccatto; Javier Cavallasca; E Civit; J Moreno; A Estevez; M Diaz; Marcela Verando; Antonio Catalan Pellet; G Gomez; Pablo Maid; Ana Beron; Gabriela Salvatierra; Marcos Mendez; A Cusa; Oscar Rillo; M Paez; M Larraude; D Sohn; M Gallo; A Conforti; Veronica Malah; Patricio Tate; A Baños
Journal:  Rheumatol Int       Date:  2014-06-20       Impact factor: 2.631

3.  Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Kath D Watson; Mark Lunt; Katie McGrother; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2010-05-05       Impact factor: 7.580

Review 4.  Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity.

Authors:  Vibeke Strand; Jasvinder A Singh
Journal:  Drugs       Date:  2010       Impact factor: 9.546

5.  Effect of Adalimumab on Work Ability Assessed in Rheumatoid Arthritis Disease Patients in Saudi Arabia (AWARDS).

Authors:  Waleed Hussain; Nahid Janoudi; Abdulsalam Noorwali; Narges Omran; Matouqa Baamer; El Hussain Assiry; Hanan Alrayes; Hanan Alosaimi; Ashraf Ibrahim; Shereen Gohary; Joan Mignuet; Hani Almoallim
Journal:  Open Rheumatol J       Date:  2015-07-10

Review 6.  The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life.

Authors:  Roy Fleischmann
Journal:  Open Access Rheumatol       Date:  2009-07-13

7.  Economic evaluation of an intervention program with the aim to improve at-work productivity for workers with rheumatoid arthritis.

Authors:  Cindy Noben; Myrthe van Vilsteren; Cécile Boot; Romy Steenbeek; Dirkjan van Schaardenburg; Johannes R Anema; Silvia Evers; Frans Nijhuis; Angelique de Rijk
Journal:  J Occup Health       Date:  2017-04-05       Impact factor: 2.708

8.  Achieving comprehensive remission or low disease activity in rheumatoid patients and its impact on workability - Saudi Rheumatoid Arthritis Registry.

Authors:  Hani Almoallim; Nahid Janoudi; Fahdah Alokaily; Zeyad Alzahrani; Shereen Algohary; Hanan Alosaimi; Suzan Attar
Journal:  Open Access Rheumatol       Date:  2019-04-17

9.  Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats.

Authors:  Aoi Koyama; Aki Tanaka; Hideto To
Journal:  J Pharm Pharmacol       Date:  2017-05-31       Impact factor: 3.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.